Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07ODC
|
||||
| Former ID |
DIB016050
|
||||
| Drug Name |
VBY- 036
|
||||
| Synonyms |
VBY-036
|
||||
| Indication | Neuropathic pain [ICD9: 356.0, 356.8; ICD10:G64, G90.0] | Phase 1 | [1] | ||
| Company |
Virobay
|
||||
| Target and Pathway | |||||
| Target(s) | Cathepsin S | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Lysosome | ||||
| Phagosome | |||||
| Antigen processing and presentation | |||||
| Tuberculosis | |||||
| NetPath Pathway | Leptin Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| Reactome | Endosomal/Vacuolar pathway | ||||
| Degradation of the extracellular matrix | |||||
| Trafficking and processing of endosomal TLR | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | Class I MHC mediated antigen processing & presentation | ||||
| Trafficking and processing of endosomal TLR | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01892891) Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing. U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of ViroBay. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.